CY1107460T1 - Αντι-ιικα παραγωγα αζαινδολης - Google Patents

Αντι-ιικα παραγωγα αζαινδολης

Info

Publication number
CY1107460T1
CY1107460T1 CY20061100420T CY061100420T CY1107460T1 CY 1107460 T1 CY1107460 T1 CY 1107460T1 CY 20061100420 T CY20061100420 T CY 20061100420T CY 061100420 T CY061100420 T CY 061100420T CY 1107460 T1 CY1107460 T1 CY 1107460T1
Authority
CY
Cyprus
Prior art keywords
azandol
virus
derivatives
chemicals
series
Prior art date
Application number
CY20061100420T
Other languages
English (en)
Inventor
Tao Wang
Owen B Wallace
Zhongxing Zhang
Nicholas A Meanwell
John A Bender
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22675206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107460(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1107460T1 publication Critical patent/CY1107460T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία σειρά χημικών ουσιών που εκφράζουν ανασταλτική HIV-1 δραστηριότητα.
CY20061100420T 2000-02-22 2006-03-27 Αντι-ιικα παραγωγα αζαινδολης CY1107460T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18400400P 2000-02-22 2000-02-22
EP01904970A EP1257276B1 (en) 2000-02-22 2001-01-19 Antiviral azaindole derivatives

Publications (1)

Publication Number Publication Date
CY1107460T1 true CY1107460T1 (el) 2012-12-19

Family

ID=22675206

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100420T CY1107460T1 (el) 2000-02-22 2006-03-27 Αντι-ιικα παραγωγα αζαινδολης

Country Status (32)

Country Link
US (1) US20020061892A1 (el)
EP (1) EP1257276B1 (el)
JP (1) JP3868814B2 (el)
KR (1) KR100496574B1 (el)
CN (1) CN1404392A (el)
AR (1) AR029469A1 (el)
AT (1) ATE314072T1 (el)
AU (2) AU2001232895B2 (el)
BR (1) BRPI0108485B1 (el)
CA (1) CA2400700C (el)
CO (1) CO5271657A1 (el)
CY (1) CY1107460T1 (el)
DE (1) DE60116260T2 (el)
DK (1) DK1257276T3 (el)
EG (1) EG24669A (el)
ES (1) ES2254367T3 (el)
HK (1) HK1052132A1 (el)
HU (1) HU229992B1 (el)
IL (1) IL150734A0 (el)
MX (1) MXPA02008113A (el)
MY (1) MY128458A (el)
NO (1) NO323564B1 (el)
NZ (1) NZ520317A (el)
PE (1) PE20020786A1 (el)
PL (1) PL357434A1 (el)
PT (1) PT1257276E (el)
RU (1) RU2259372C2 (el)
TR (1) TR200201961T2 (el)
TW (1) TWI293629B (el)
UY (1) UY26593A1 (el)
WO (1) WO2001062255A1 (el)
ZA (1) ZA200206073B (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069266A1 (en) * 2001-02-02 2003-04-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003072028A2 (en) * 2002-02-23 2003-09-04 Bristol-Myers Squibb Company Method of treating hiv infection by preventing interaction of cd4 and gp120
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
CN1953985B (zh) * 2004-03-15 2010-06-09 布里斯托尔-迈尔斯斯奎布公司 哌嗪和取代的哌啶抗病毒药物的前药
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
PE20060430A1 (es) 2004-06-09 2006-05-25 Glaxo Group Ltd Derivados de pirrolopiridina como moduladores de los receptores cannabinoides
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US7598380B2 (en) 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
KR20100020478A (ko) * 2007-06-18 2010-02-22 사노피-아벤티스 Ｐ2ｙ12 길항제로서의 피롤 유도체
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
DK2240482T3 (da) 2008-01-31 2013-10-21 Sanofi Sa Cykliske azaindol-3-carboxamider, deres fremstilling og deres anvendelse som lægemidler
DK2323633T3 (da) * 2008-09-04 2012-07-09 Bristol Myers Squibb Co Stabil, farmaceutisk sammensætning til optimeret indgivelse af en hiv-bindingshæmmer
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN102746295B (zh) * 2012-06-20 2014-10-15 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
EP2895471B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Piperidine amide derivatives as hiv attachment inhibitors
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
CN109528749B (zh) * 2017-09-22 2023-04-28 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CN112430223B (zh) * 2020-11-24 2022-11-25 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用

Also Published As

Publication number Publication date
KR100496574B1 (ko) 2005-06-22
CN1404392A (zh) 2003-03-19
MY128458A (en) 2007-02-28
HUP0301508A3 (en) 2004-08-30
IL150734A0 (en) 2003-02-12
HU229992B1 (en) 2015-04-28
ZA200206073B (en) 2003-10-30
HUP0301508A2 (hu) 2003-09-29
NO20023981L (no) 2002-10-17
AU3289501A (en) 2001-09-03
UY26593A1 (es) 2001-09-28
EG24669A (en) 2010-04-11
JP2003523392A (ja) 2003-08-05
RU2002125494A (ru) 2004-03-20
PL357434A1 (en) 2004-07-26
AR029469A1 (es) 2003-07-02
US20020061892A1 (en) 2002-05-23
TR200201961T2 (tr) 2002-12-23
EP1257276A1 (en) 2002-11-20
CA2400700A1 (en) 2001-08-30
DE60116260D1 (de) 2006-02-02
RU2259372C2 (ru) 2005-08-27
EP1257276A4 (en) 2004-10-27
JP3868814B2 (ja) 2007-01-17
BRPI0108485B1 (pt) 2016-08-23
ATE314072T1 (de) 2006-01-15
AU2001232895B2 (en) 2005-03-17
CA2400700C (en) 2010-10-26
MXPA02008113A (es) 2003-01-28
ES2254367T3 (es) 2006-06-16
EP1257276B1 (en) 2005-12-28
NZ520317A (en) 2004-05-28
DK1257276T3 (da) 2006-04-10
NO323564B1 (no) 2007-06-11
NO20023981D0 (no) 2002-08-21
DE60116260T2 (de) 2006-08-31
WO2001062255A1 (en) 2001-08-30
HK1052132A1 (en) 2003-09-05
KR20020073598A (ko) 2002-09-27
PE20020786A1 (es) 2002-09-06
TWI293629B (el) 2008-02-21
BR0108485A (pt) 2003-04-22
PT1257276E (pt) 2006-05-31
CO5271657A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
CY1107460T1 (el) Αντι-ιικα παραγωγα αζαινδολης
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
CO4970820A1 (es) Sal de bisulfato del inhibidor de la vih-proteasa
CY1110489T1 (el) Παραγωγα ισοκινολινης
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1121057T1 (el) Συμπυκνωμα ελαιωδους εναιωρηματος
TR200000782T2 (tr) Resorsinol türevleri.
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
ATE498134T1 (de) Nachweis von staphylococcus
DE60234760D1 (de) Phenylindole zur behandlung von hiv
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
MA25782A1 (fr) Inhibitions de metalloprotease contenant une chaine laterale heterocyclique.
DE50004334D1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
CY1113959T1 (el) Χρηση λιποσωματων pvp-ιωδιου για θεραπεια ακμης
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
CY1112888T1 (el) Μεθοδος παρασκευης της (s)-παντοπραζολης
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
SE9901077D0 (sv) Novel use
ECSP056238A (es) Tableta que comprende fluvastatina y carmelosa de calcio.
ATE410235T1 (de) Behandlung von ballastwasser
HUP0000362A2 (hu) Madár-reovírusok új antigén osztálya